Clinical Trial Search

Primary: Number of Participants Not Giving Birth Before Week 32 and Week 34 of Gestation — 73; 71; 67; 66 Participants

Primary: Overall Response Rate (Complete Response and Partial Response) After Three Inductions Cycles of Treatment. — 71 percentage of patients

Primary: Number of Patients Who Achieve a Greater Than or Equal to 50% Decline in Serum Prostate Specific Antigen (PSA) — 1 Participants

Primary: Post- Cue Exposure Craving Nicotine Patch — 25.58; 25.6 score on a scale

Primary: Area Under the Effect Curve for Absolute Neutrophil Count (AUECANC): Cycle 0 — 3900.482; 5880.985 hour*10^9 Neutrophils per Liter

Primary: Change From Baseline to Last 5 Days of Treatment in the Average Evening Pain Intensity In the Target Knee When Walking on a Flat Surface Using a Mixed Model for Repeated…

Primary: Summary of Participants With Treatment-Emergent Adverse Events (TEAE) — 4; 4; 7; 11 Participants

Primary: 11C Raclopride Binding Potential in Caudate — 3.25; 3.45 mCi/ml

Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures — 5.37; 5.60…

Primary: Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale — -7; -33 T-Score

Primary: Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention — 5.45; 6.61; 6.64; 6.57 score on a scale — p=.211

Primary: Frequency of Epistaxis — 7.0; 8.0; 7.5; 8.0 Bleeding episodes per week — p=0.97

Primary: Time to Progression — 3.12; 1.64 months

Primary: Percentage of Participant With Response at Week 16 — 59 percentage of patients

Primary: Overall Survival